Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 10, 2026, 7:30 AM ET
Ardelyx will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026.
Nasdaq: $ARDXIBSRELA / XPHOZAHTwo approved productsAccess and execution risk
ARDX Stock Hub: Ardelyx News, IBSRELA Growth and XPHOZAH Access
Ardelyx’s Q3 combines product growth with positive quarterly operating cash flow. Net product sales were $125.455 million, total GAAP revenue $127.655 million and net loss $0.737 million. September cash and investments were $285.338 million against $250 million drawn loan principal. ACCEL enrollment is complete; a formulation patent was due to issue on November 10, according to the USPTO notice reported by the company. The November 3 completed close was $3.03, before the after-close results.
Full research report · PDF
Ardelyx research updated November 4, 2026
32 pages. All 22 analytical chapters: Q3 and nine-month earnings, cash conversion, dated Q2 financials, IBSRELA access, XPHOZAH reimbursement, ACCEL trial design and enrollment, RDX10531, patents, secured debt and covenants, equity dilution, ownership, filed litigation and risks. Daily candles, volume and SMA 50/200 on page 2 through November 3, before the Q3 release. Personal use only: redistribution prohibited.
Next dated event
November 17, 2026 · Jefferies fireside chat, London, 11:30 a.m. GMT (6:30 a.m. ET)
Ardelyx said on November 3 that the U.S. Patent and Trademark Office had notified it that the patent “Oral Formulation of a Therapeutic Compound” was due to issue on November 10, 2026, with an expiration date of December 6, 2041. According to the company, it covers the commercial formulations of both IBSRELA and XPHOZAH. An issued patent can still be challenged. Source: Q3 2026 results release, November 3.
Third-quarter results were reported on November 3, followed by the 4:30 p.m. Eastern call. December 20 is the contractual deadline for the optional $50M Term G loan draw, rather than a clinical event; ACCEL topline data are expected in the second half of 2027. Ardelyx is scheduled for a fireside chat at the Jefferies Global Healthcare Conference in London on November 17 at 11:30 a.m. GMT (6:30 a.m. ET), with a live webcast. Conference announcement.
ARDX stock at a glance
Close – November 3
$3.03
Completed regular session; before after-close results
Where Ardelyx stands now
Q3 net product sales grew 19% to $125.455 million: IBSRELA $96.286 million and XPHOZAH $29.169 million. Total GAAP revenue was $127.655 million, operating income $4.023 million and net loss $0.737 million. Rounded loss per share of $0.00 represents a small loss, rather than a net profit. Nine-month net loss was $55.063 million. Company disclosure.
September cash of $46.317 million and investments of $239.021 million totaled $285.338 million. Q3 operating cash flow was positive $2.171 million, while nine-month operating cash use remained $36.465 million. Cash alone fell as securities increased; net investment purchases are different from operating burn. H1 comparison. Company disclosure.
Annual guidance remains IBSRELA $350-370 million, XPHOZAH $110-120 million and R&D plus SG&A below $500 million. The supplemental materials project profitability in 2027; achieving it depends on demand, access, expense discipline and working capital. Company disclosure.
The constructive case
IBSRELA growth and positive quarterly operating cash flow improve the operating baseline. Completed ACCEL enrollment advances a clinical milestone; formulation protection and disciplined commercial investment could support longer-term growth.
The cautious case
One quarter’s cash generation can reverse with working capital or spending. Access barriers, $250 million secured principal, employee awards, litigation and trial uncertainty remain. Patent issuance and recruitment do not demonstrate efficacy or guarantee revenue.
Latest Ardelyx news
Nov 10, 2026
Ardelyx to participate at the Jefferies Global Healthcare Conference in London
Ardelyx announced its participation in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026. A live webcast will be available on the Events and Presentations page at ir.ardelyx.com, and a replay will be available following the event.
Nov 3, 2026
Ardelyx reports third quarter 2026 financial results and provides business update
Ardelyx reported total product revenue of $125.5 million for the quarter ended September 30, 2026, reflecting 19% growth year-over-year. IBSRELA revenue was $96.3 million, reflecting year-over-year growth of 23%, and XPHOZAH revenue was $29.2 million. Cash, cash equivalents and short-term investments totaled $285.3 million as of September 30, 2026, and full-year 2026 IBSRELA revenue guidance was reiterated to be between $350 and $370 million.
Nov 3, 2026
Ardelyx completes enrollment in Phase 3 ACCEL trial of IBSRELA in chronic idiopathic constipation
Ardelyx has fully enrolled all patients in the Phase 3 ACCEL clinical trial, ahead of schedule, evaluating IBSRELA (tenapanor) for chronic idiopathic constipation in adults. The randomized, double-blind, placebo-controlled trial doses IBSRELA twice daily for 26 consecutive weeks. Topline data is expected in the second half of 2027. IBSRELA is approved in the United States for irritable bowel syndrome with constipation in adults but is not approved for chronic idiopathic constipation.
Oct 23, 2026
ASN real-world analysis reports phosphate reductions
An observational analysis of more than 1,400 adults on dialysis found adjusted serum phosphate reductions of 0.80–1.55 mg/dL at six months after XPHOZAH initiation. Across groups, 60–70% remained on tenapanor at 180 days. The analysis was not randomized and does not establish a new approved use.
Oct 20, 2026
Third-quarter call set for November 3
Ardelyx scheduled its Q3 results discussion and business update for November 3 at 4:30 p.m. Eastern. This is the next announced opportunity to assess sales, patient access, collections and spending after the August outlook reduction.
Oct 13, 2026
Shareholder derivative complaint filed
A verified shareholder derivative complaint was filed in the District of Massachusetts, No. 1:26-cv-14635, with Ardelyx as nominal defendant. It is distinct from the September securities class action. The filing contains allegations, not findings of liability.
ARDX stock catalysts: quarterly execution and ACCEL
- November 3, 2026 — Q3 results and business update: product revenue $125.5M, FY2026 guidance reiterated; call held at 4:30 p.m. Eastern. Completed
- November 3, 2026 — ACCEL enrollment completed ahead of schedule, according to the company; the August guidance had pointed to year-end 2026. Completed
- November 10, 2026 — U.S. Patent No. 12,788,750 due to issue, according to the USPTO notice reported by the company; expiration December 6, 2041. Issue date per USPTO notice reported by the company
- November 17, 2026 · 6:30 a.m. ET — Fireside chat at the Jefferies Global Healthcare Conference, London (11:30 a.m. GMT), with live webcast and replay. Company-announced event
- December 20, 2026 — Deadline to elect the optional $50M Term G loan draw; not cash already received. Contractual financing window
- February 26, 2027 — ACCEL primary-completion estimate in the June 4, 2026 registry record, distinct from the later company topline window. Registry estimate
- H2 2027 — ACCEL topline results window; no exact day specified. Company guidance
Q3 results and patent notice · Q3 filing and loan terms · ACCEL registry · November 3 enrollment release.
IBSRELA, XPHOZAH and the clinical expansion
IBSRELA is approved for adults with IBS-C. XPHOZAH is add-on treatment to reduce serum phosphorus in specified adults with CKD on dialysis after inadequate phosphate-binder response or intolerance. Both contain tenapanor, with different indications and prescribing restrictions. CIC remains investigational. Company disclosure.
ACCEL was fully enrolled ahead of schedule on November 3; topline is expected H2 2027. The company describes a randomized, double-blind, placebo-controlled study with 26 consecutive weeks of treatment. The June registry record and the November company enrollment update have different dates. RDX10531 remains in IND-enabling studies. Enrollment and trial design. Company disclosure.
The formulation patent 12,788,750 was due to issue on November 10, 2026 and expires December 6, 2041, according to the company’s USPTO notice. It is distinct from patent 12,539,299 issued February 3, 2026 with November 26, 2042 expiry; the new patent does not replace that later-dated protection. February patent announcement. Company disclosure.
ARDX cash, secured debt, dilution and filed litigation
The SLR loan had $250 million drawn principal, $252.360 million carrying debt and optional $50 million Term G capacity available through December 20, 2026. Undrawn borrowing is separate from reported cash. The covenant combines trailing-six-month net product revenue and qualifying pledged cash against principal; the entire investment balance is not automatically qualifying cash. Company disclosure.
Common shares were 251,372,553 on October 27, versus 251,030,827 at September 30. The $100 million ATM had no sales through September 30. Q3 stock compensation was $15.101 million; awards, options and possible future issuance affect ownership. The approved nine-million-share plan expansion increases award capacity, rather than representing an immediate public offering. Company disclosure.
The September 17 securities class action and October 13 derivative action are separate proceedings with overlapping factual allegations. The company contests the claims and cannot reasonably estimate a loss amount or range. Allegations are not findings of misconduct. The September filing describes both proceedings. Company disclosure.
Merlintrader Health Score · $ARDX
3.00out of 5
Reviewed November 10, 2026, after the announcement of the November 17 Jefferies fireside chat, which adds no new financial or clinical data; scores unchanged from the November 4, 2026 reassessment. Weighted calculation: 3.0 x 30% + 3.0 x 30% + 3.0 x 20% + 3.0 x 10% + 3.0 x 10% = 3.00 / 5. Financial and operational robustness over twelve to eighteen months; not an investment recommendation or clinical-success probability.
Red flags
- Nine-month losses and operating cash use continue despite a stronger Q3.
- Patient access and reimbursement affect conversion of demand into revenue.
- Receivables, inventory and rebate liabilities can change quarterly cash conversion.
- Secured debt and covenants constrain flexibility; optional borrowing has a December deadline.
- ACCEL remains investigational; recruitment is distinct from efficacy.
- Patent issuance, scope, enforceability and commercial outcomes are different questions.
- Stock compensation, awards and potential ATM use can affect ownership.
- Securities and derivative complaints contain contested allegations with uncertain outcomes.
ARDX Stock FAQ: Ardelyx Questions Answered
When is the next ARDX stock catalyst?
Ardelyx’s next dated event is a fireside chat at the Jefferies Global Healthcare Conference in London on November 17, 2026 at 11:30 a.m. GMT (6:30 a.m. ET); after that, December 20 is the deadline to elect the optional Term G loan draw, and ACCEL topline data are expected in H2 2027. U.S. Patent No. 12,788,750, which the company says covers the commercial formulations of IBSRELA and XPHOZAH and expires December 6, 2041, was due to issue on November 10, 2026, according to the USPTO notice reported by the company. Q3 2026 results were reported on November 3. Q3 2026 results and patent notice. Term G contractual deadline.
Are Ardelyx’s IBSRELA and XPHOZAH FDA approved?
Yes: Ardelyx’s August 6, 2026 update describes approved tenapanor products IBSRELA for adults with IBS-C and XPHOZAH for specified adults with CKD on dialysis and hyperphosphatemia. XPHOZAH is add-on treatment after inadequate response to phosphate binders or intolerance to any dose. The ACCEL chronic idiopathic constipation indication remains investigational. Approved indications and clinical pipeline.
How much cash does Ardelyx have, and how long will it last?
Ardelyx held $285.338 million cash and short-term investments at September 30, 2026, against $250 million drawn loan principal and $252.360 million carrying debt. Q3 operating cash flow was positive $2.171 million, while nine-month operating use was $36.465 million. The $50 million optional Term G election runs through December 20, 2026. The company expects its existing resources to fund planned operations for at least one year from issuance, subject to assumptions. September liquidity. H1 cash-flow comparison.
Is ARDX stock at risk of dilution?
Yes: Ardelyx reported 251,372,553 common shares on October 27, 2026, up from 249,187,572 on July 30. Shareholders approved nine million additional equity-plan shares in June, registered in August; that increases award capacity rather than constituting an immediate public offering. Options, unvested RSUs and potential future financing can expand the ownership denominator. Common shares and equity awards. Plan approval. Plan-share registration. June filing and July cover count.
When does Ardelyx report earnings?
As of November 4, 2026, Ardelyx has not announced its next earnings date. It reported Q3 results on November 3 and held its call at 4:30 p.m. Eastern. Product sales were $125.455 million, total revenue $127.655 million and net loss $0.737 million; annual guidance was reiterated. Q3 results. Company events.
What does Ardelyx do?
In its November 3, 2026 update, Ardelyx describes a commercial-stage biopharmaceutical business focused on medicines for significant unmet needs. IBSRELA treats adults with IBS-C, and XPHOZAH reduces serum phosphorus in specified adults with CKD on dialysis as add-on therapy. Both contain tenapanor. ACCEL tests an investigational CIC indication, while RDX10531 remains in IND-enabling development. Business update. Pipeline stage.
Why did Ardelyx cut IBSRELA guidance?
Ardelyx’s August 6, 2026 update reduced FY2026 IBSRELA guidance to $350–370 million because of patient-access and reimbursement constraints; on November 3 it reiterated that range after Q3 IBSRELA revenue of $96.3 million. Q2 product sales had reached $118.1 million: IBSRELA $86.2 million and XPHOZAH $31.9 million. The guidance change concerned commercial conversion of demand, without changing established clinical evidence. ACCEL completed enrollment ahead of schedule, Ardelyx announced on November 3, 2026, and topline data are expected in H2 2027; the registry’s February 26, 2027 primary-completion estimate describes a different milestone. Sales, guidance and ACCEL timing. ACCEL registry. November 3 guidance and enrollment update.
Are Ardelyx’s two recent shareholder cases the same lawsuit?
No: the September 17, 2026 securities class action is Massachusetts case 1:26-cv-14270; the October 13 filing is a separate shareholder derivative action, case 1:26-cv-14635. Ardelyx is nominal defendant in the derivative case. The complaints contain allegations, without establishing adjudicated liability. Filed securities complaint. Filed derivative complaint.
Primary sources
- November 10, 2026 — Fireside chat at the Jefferies Global Healthcare Conference in London on November 17
- November 3 Form 10-Q
- November 3 earnings release
- November 3 supplemental presentation
- November 3 completed ACCEL enrollment
- Q3 2026 results, guidance and patent notice, November 3, 2026 (SEC Exhibit 99.1)
- Q3 2026 Form 10-Q: cash, debt, shares and litigation
- ACCEL enrollment completed, November 3, 2026 (company release, wire copy)
- Q2 2026 Form 10-Q: cash, debt, dilution and business
- Q2 results and guidance, August 6, 2026
- Q3 call announcement, October 20, 2026
- ACCEL trial record, NCT07382167
- ASN real-world findings, October 23, 2026
- Primary securities class-action complaint
- Primary shareholder derivative complaint
- Nasdaq short-interest report
- Nasdaq historical trading volume
- Annual-meeting results and plan-share approval
- August 10 Form S-8 registration
- Rubric Schedule 13G, August 14, 2026
- Millennium Schedule 13G/A, August 11, 2026
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ARDX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
